Table 2.
Clinical characteristics and chemistry results according to mean platelet volume
| Variables | I tert < 10.0 fL (n = 37) |
II tert 10.0–11.0 fL (n = 42) |
III tert ≥11.0 fL (n = 33) |
P |
|---|---|---|---|---|
| Age, yrs. | 58.2 ± 10.3 | 55.7 ± 12.1 | 57.4 ± 9.2 | 0.566 |
| Male, n (%) | 33(89.2) | 31(73.8) | 27(81.8) | 0.216 |
| BMI, kg/m2 | 26.1 ± 3.5 | 25.9 ± 3.4 | 25.5 ± 2.6 | 0.758 |
| LVEF, % | 60.0(53.0, 65.0) | 63.0(60.0, 65.0) | 65.0(58.0, 68.0) | 0.026 |
| Risk factors | ||||
| Hypertension, n (%) | 20(54.1) | 20(47.6) | 24(72.7) | 0.083 |
| Diabetes, n (%) | 14(37.8) | 14(33.3) | 7(21.2) | 0.304 |
| Hyperlipidemia, n (%) | 34(91.9) | 38 (90.5) | 29(87.9) | 0.850 |
| Past history | ||||
| Previous PCI, n (%) | 15(40.5) | 12(28.6) | 10(30.3) | 0.489 |
| Previous MI, n (%) | 29(78.4) | 28(66.7) | 16(48.5) | 0.031 |
| Previous stroke, n (%) | 4(10.8) | 4(9.5) | 6(18.2) | 0.494 |
| Medications | ||||
| Statins, n (%) | 37(100.0) | 42(100.0) | 33(100.0) | 1.000 |
| ACEI, n (%) | 17(45.9) | 14(33.3) | 9(27.3) | 0.245 |
| ARB, n (%) | 6(16.2) | 3(7.1) | 6(18.2) | 0.313 |
| β-blocker, n (%) | 36(97.3) | 34(81.0) | 28(84.8) | 0.078 |
| Laboratory | ||||
| Hemoglobin, g/L | 140.0 ± 13.0 | 147.0 ± 13.2 | 148.8 ± 11.9 | 0.011 |
| LDL-C, mmol/L | 2.4(1.7, 2.8) | 2.2(1.6, 2.8) | 2.0(1.7, 2.2) | 0.457 |
| HsCRP, mg/L | 3.1(1.2, 8.4) | 1.8(0.9, 4.7) | 1.5(0.5, 6.7) | 0.232 |
| AST, U/L | 25.0(20.5, 85.0) | 25.5(20.8, 38.2) | 21.0(16.5, 28.0) | 0.010 |
| ALT, U/L | 26.0(22.0, 42.5) | 32.0(21.5, 52.0) | 29.0(17.0, 40.0) | 0.474 |
| Platelet, 109 cells/L | 257.3 ± 73.4 | 243.9 ± 63.2 | 201.4 ± 48.3 | 0.001 |
| Maximal LT changes in response to 5 μM ADP, % | 17.0(12.4, 25.7) | 20.6(12.1, 36.5) | 32.0(16.4, 51.5) | 0.006 |
| PRI, % | 21(11.5, 28.0) | 31.0(23.0, 66.5) | 61.0(30.5, 79.0) | < 0.001 |
| Percentage of HPR-LTA, % | 0(0) | 6(14.3) | 5(15.2) | 0.049 |
| Percentage of HPR-VASP, % | 4(10.8) | 15(35.7) | 20(60.6) | < 0.001 |
| Dual antiplatelet therapy | ||||
| Traditional therapy, n (%) | 6(16.2) | 18(42.9) | 22(66.7) | < 0.001 |
| New therapy, n (%) | 31(83.8) | 24(57.1) | 11(33.3) | < 0.001 |
Values are mean ± SD if the distribution is normal; median (interquartile range) if skewed; number, n (proportions, %) for categorical variables
ADP Adenosine diphosphate, HPR High on-treatment platelet reactivity, LT Light transmittance, PRI Platelet response index. Others were as Table 1